Aplastic Anemia Pipeline Analysis: 08+ Companies are working to improve the Treatment Space

DelveInsight's, "Aplastic Anemia Pipeline Insight, 2022," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Aplastic Anemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key takeaways from the Aplastic Anemia Pipeline Report
• DelveInsight's Aplastic Anemia Pipeline report depicts a robust space with 08+ active players working to develop 08+ pipeline therapies for Aplastic Anemia.
• Major companies such as Kyowa Kirin Co., Ltd., Regeneron Pharmaceuticals, Foresee Pharmaceuticals, Omidubicel, Cellenkos, Hemogenyx, Gamida Cell Ltd., Pfizer, and others are developing potential drug candidates to improve the Aplastic Anemia treatment scenario.
• Promising Aplastic Anemia Pipeline Therapies such as PF-06462700, REGN7257, BL-8040, and others
• The companies and academics are working to assess challenges and seek opportunities that could influence Aplastic Anemia R&D. The therapies under development are focused on novel approaches for Aplastic Anemia.

Get an overview of Aplastic Anemia Clinical Trials Analysis @ https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Aplastic Anemia Overview
Aplastic anemia is a medical condition that damages stem cells in a person's bone marrow. These cells are responsible for making red blood cells, white blood cells, and platelets, which are vital to human health. A rare and serious condition, aplastic anemia can develop at any age. It can occur suddenly, or it can come on slowly and worsen over time. It can be mild or severe. Treatment for aplastic anemia might include medications, blood transfusions or a stem cell transplant, also known as a bone marrow transplant. The most common cause of aplastic anemia is from your immune system attacking the stem cells in your bone marrow. Other factors that can injure bone marrow and affect blood cell production include: Radiation and chemotherapy treatments, exposure to toxic chemicals, use of certain drugs, autoimmune disorders, a viral infection and unknown factors.

Recent Breakthroughs of Aplastic Anemia Treatment Landscape
• In June 2019, Kyowa Hakko Kirin received the partial change approval of Romiplate for additional treatment of Aplastic Anemia patients who have had an inadequate response to conventional therapy from Japan's Ministry of Health, Labour, and Welfare (MHLW).
• Hetrombopag, a thrombopoietin receptor agonist being developed by Jiangsu Hengrui Medicine, is registered for aplastic anemia in China to treat Aplastic Anemia.
• Omidubicel is an advanced cell therapy under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies. A poster presentation at the American Society of Hematology (ASH) 62nd Annual Meeting in December 2020 showed that patients with severe aplastic anemia treated with omidubicel achieved sustained early engraftment.
• CK 0801 is being developed and investigated in preclinical studies by Cellenkos and the MD Anderson Cancer Center.
• HemoGenyx has been granted FDA orphan drug designation for Hu-PHEC Liver to treat aplastic anemia, enabling a faster route to commercialization to get the therapies and treatments to patients most in need.

For further information, refer to the detailed Aplastic Anemia Pipeline Therapeutics report @ https://www.delveinsight.com/sample-request/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Aplastic Anemia Emerging Drugs
• PF-06462700: Pfizer
• REGN7257: Regeneron Pharmaceuticals
• BL-8040: BioLineRx, Ltd.

DelveInsight's Aplastic Anemia Pipeline report covers around 8+ products under different phases of clinical development like
• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Find out more about Aplastic Anemia Medication @ Aplastic https://www.delveinsight.com/report-store/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Aplastic Anemia Pipeline Report
• Coverage- Global
• Aplastic Anemia Companies- Kyowa Kirin Co., Ltd., Regeneron Pharmaceuticals, Foresee Pharmaceuticals, Omidubicel, Cellenkos, Hemogenyx, Gamida Cell Ltd., Pfizer, and others.
• Aplastic Anemia Pipeline Therapies-PF-06462700, REGN7257, BL-8040, and others

Table of Content
1. Introduction
2. Executive Summary
3. Aplastic Anemia: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Aplastic Anemia- DelveInsight's Analytical Perspective
7. In-depth Commercial Assessment
8. Aplastic Anemia Collaboration Deals
9. Late Stage Products (Phase III)
10. PF-06462700: Pfizer
11. Mid Stage Products (Phase II)
12. BL-8040: BioLineRx, Ltd.
13. Early Stage Products (Phase I/II)
14. REGN7257: Regeneron Pharmaceuticals
15. Inactive Products
16. Aplastic Anemia Key Companies
17. Aplastic Anemia Key Products
18. Aplastic Anemia- Unmet Needs
19. Aplastic Anemia- Market Drivers and Barriers
20. Aplastic Anemia- Future Perspectives and Conclusion
21. Aplastic Anemia Analyst Views
22. Aplastic Anemia Key Companies
23. Appendix

Get a holistic view of the Aplastic Anemia Drug Pipeline and Emerging Trends @ https://www.delveinsight.com/report-store/aplastic-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

This release was published on openPR.